Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Direct detection of early-stage cancers using circulating tumor DNA.

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, ├śrntoft T, Nielsen HJ, Andersen CL, Velculescu VE.

Sci Transl Med. 2017 Aug 16;9(403). pii: eaan2415. doi: 10.1126/scitranslmed.aan2415.

PMID:
28814544
2.

Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.

Xia L, Li Z, Zhou B, Tian G, Zeng L, Dai H, Li X, Liu C, Lu S, Xu F, Tu X, Deng F, Xie Y, Huang W, He J.

Sci Rep. 2017 Aug 8;7(1):7526. doi: 10.1038/s41598-017-06106-1.

3.

Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.

Cheng F, Su L, Qian C.

Oncotarget. 2016 Jul 26;7(30):48832-48841. doi: 10.18632/oncotarget.9453. Review.

4.

Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing.

Hellwig S, Nix DA, Gligorich KM, O'Shea JM, Thomas A, Fuertes CL, Bhetariya PJ, Marth GT, Bronner MP, Underhill HR.

PLoS One. 2018 Jul 25;13(7):e0197333. doi: 10.1371/journal.pone.0197333. eCollection 2018.

5.

Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection.

Fiala C, Diamandis EP.

BMC Med. 2018 Oct 2;16(1):166. doi: 10.1186/s12916-018-1157-9.

6.

5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages.

Song CX, Yin S, Ma L, Wheeler A, Chen Y, Zhang Y, Liu B, Xiong J, Zhang W, Hu J, Zhou Z, Dong B, Tian Z, Jeffrey SS, Chua MS, So S, Li W, Wei Y, Diao J, Xie D, Quake SR.

Cell Res. 2017 Oct;27(10):1231-1242. doi: 10.1038/cr.2017.106. Epub 2017 Aug 18.

7.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD.

Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.

8.

Liquid Biopsy Technique May Allow Early Screening.

[No authors listed]

Cancer Discov. 2017 Nov;7(11):1207. doi: 10.1158/2159-8290.CD-NB2017-125. Epub 2017 Sep 13.

9.

The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.

Cree IA, Uttley L, Buckley Woods H, Kikuchi H, Reiman A, Harnan S, Whiteman BL, Philips ST, Messenger M, Cox A, Teare D, Sheils O, Shaw J; UK Early Cancer Detection Consortium.

BMC Cancer. 2017 Oct 23;17(1):697. doi: 10.1186/s12885-017-3693-7. Review.

10.

Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.

Beije N, Helmijr JC, Weerts MJA, Beaufort CM, Wiggin M, Marziali A, Verhoef C, Sleijfer S, Jansen MPHM, Martens JWM.

Mol Oncol. 2016 Dec;10(10):1575-1584. doi: 10.1016/j.molonc.2016.10.001.

11.

Detection and localization of surgically resectable cancers with a multi-analyte blood test.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N.

Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

12.

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.

Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA Jr, Velculescu VE.

Sci Transl Med. 2012 Nov 28;4(162):162ra154. doi: 10.1126/scitranslmed.3004742.

13.

Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.

Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F.

Ann Oncol. 2017 Mar 1;28(3):642-650. doi: 10.1093/annonc/mdw670.

14.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.

Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, Park YS, Lim HY, Eltoukhy H, Kang WK, Lee WY, Kim HC, Park K, Lee J, Talasaz A.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.

15.

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.

Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, Massard C, Cassier PA, Miranda S, Clark J, Denholm KA, Thway K, Gonzalez De Castro D, Attard G, Molife LR, Kaye SB, Banerji U, de Bono JS.

PLoS One. 2012;7(11):e47020. doi: 10.1371/journal.pone.0047020. Epub 2012 Nov 7.

16.

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.

Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, Salari R, Kirkizlar E, Sigurjonsson S, Pelham R, Kareht S, Zimmermann B, Swanton C.

Ann Oncol. 2016 May;27(5):862-7. doi: 10.1093/annonc/mdw037. Epub 2016 Jan 28.

PMID:
26823523
17.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.

Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.

18.

Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.

Liao W, Yang H, Xu H, Wang Y, Ge P, Ren J, Xu W, Lu X, Sang X, Zhong S, Zhang H, Mao Y.

Oncotarget. 2016 Jun 28;7(26):40481-40490. doi: 10.18632/oncotarget.9629.

19.

Grail to pour $1 billion into blood test to detect early cancer.

Sheridan C.

Nat Biotechnol. 2017 Feb 8;35(2):101-102. doi: 10.1038/nbt0217-101. No abstract available.

PMID:
28178244
20.

Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.

Yao Y, Liu J, Li L, Yuan Y, Nan K, Wu X, Zhang Z, Wu Y, Li X, Zhu J, Meng X, Wei L, Chen J, Jiang Z.

Oncotarget. 2017 Jan 10;8(2):2130-2140. doi: 10.18632/oncotarget.12883.

Supplemental Content

Support Center